{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:05:23Z","timestamp":1779437123234,"version":"3.53.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672371"],"award-info":[{"award-number":["81672371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373223"],"award-info":[{"award-number":["82373223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473208"],"award-info":[{"award-number":["82473208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Industry High-Quality Development Plan","award":["25S11903600"],"award-info":[{"award-number":["25S11903600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) constitutes a formidable global health challenge. Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), has gradually become a cornerstone therapeutic agent for advanced HCC; however, the emergence of drug resistance severely compromises its clinical efficacy and remains a major obstacle to improving patient outcomes. In this study, we identified key genes associated with lenvatinib resistance, among which regulator of nuclear pre-mRNA domain-containing protein 1A (RPRD1A) emerged as a prominent candidate. Functional assays demonstrated that RPRD1A overexpression significantly reduces the sensitivity of HCC to lenvatinib, whereas its knockdown restores drug responsiveness. Mechanistically, RPRD1A competes with RNA polymerase II-associated protein 2 (RPAP2) for binding to RNA polymerase II (RNA Pol II), thereby derepressing integrin subunit alpha 5 (ITGA5) transcription via a c-JUN-dependent pathway. Upregulated ITGA5 subsequently activates focal adhesion kinase (FAK) signaling, which critically drives lenvatinib resistance. Notably, combined treatment with lenvatinib and either the ITGA5 inhibitor volociximab or the FAK inhibitor defactinib effectively reversed lenvatinib resistance in preclinical models. Furthermore, clinical analyses revealed that elevated expression of RPRD1A and ITGA5 correlates with poor response to lenvatinib in HCC patients, reinforcing their potential as predictive biomarkers for therapeutic resistance. Collectively, our results demonstrate that co-targeting the RPRD1A-ITGA5-FAK signaling axis in combination with lenvatinib represents a promising strategy to improve therapeutic efficacy in HCC.<\/jats:p>","DOI":"10.1186\/s43556-026-00459-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:12:31Z","timestamp":1779433951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis"],"prefix":"10.1186","volume":"7","author":[{"given":"Xiaomeng","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmiao","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhu","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"10204","key":"459_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30427-1.","journal-title":"Lancet"},{"issue":"3","key":"459_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"459_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2025","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: Global Burden of Disease Study. J Hepatol. 2025;82(5):851\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.031.","journal-title":"J Hepatol"},{"issue":"6","key":"459_CR4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"issue":"4","key":"459_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203\u201322. https:\/\/doi.org\/10.1038\/s41575-022-00704-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"459_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947\u201355. https:\/\/doi.org\/10.1097\/SLA.0000000000000710.","journal-title":"Ann Surg"},{"issue":"3","key":"459_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.amjms.2017.05.014","volume":"354","author":"H Zou","year":"2017","unstructured":"Zou H, Zhu CZ, Wang C, Wang ZS, Ma X, Han B, et al. Recurrence of Barcelona Clinic Liver Cancer Stage A hepatocellular carcinoma after hepatectomy. Am J Med Sci. 2017;354(3):262\u20137. https:\/\/doi.org\/10.1016\/j.amjms.2017.05.014.","journal-title":"Am J Med Sci"},{"issue":"3","key":"459_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/SLA.0000000000006056","volume":"279","author":"Z Moazzam","year":"2024","unstructured":"Moazzam Z, Alaimo L, Endo Y, Lima HA, Woldesenbet S, Rueda BO, et al. A prognostic model to predict survival after recurrence among patients with recurrent hepatocellular carcinoma. Ann Surg. 2024;279(3):471\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000006056.","journal-title":"Ann Surg"},{"issue":"4","key":"459_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"32","key":"459_CR10","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067\u201375. https:\/\/doi.org\/10.1200\/JCO.2012.45.8372.","journal-title":"J Clin Oncol"},{"issue":"28","key":"459_CR11","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509\u201316. https:\/\/doi.org\/10.1200\/JCO.2012.47.3009.","journal-title":"J Clin Oncol"},{"issue":"6","key":"459_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559\u201366. https:\/\/doi.org\/10.1200\/JCO.2013.53.7746.","journal-title":"J Clin Oncol"},{"issue":"1","key":"459_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113\u201322. https:\/\/doi.org\/10.1007\/s00535-019-01642-1.","journal-title":"J Gastroenterol"},{"issue":"10126","key":"459_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"6","key":"459_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665\u201374. https:\/\/doi.org\/10.1007\/s40265-019-01116-x.","journal-title":"Drugs"},{"issue":"6","key":"459_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641\u201353. https:\/\/doi.org\/10.1002\/cam4.1517.","journal-title":"Cancer Med"},{"issue":"4","key":"459_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41388-020-01544-0","volume":"40","author":"M Li","year":"2021","unstructured":"Li M, Ma D, Chang Z. Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers. Oncogene. 2021;40(4):705\u201316. https:\/\/doi.org\/10.1038\/s41388-020-01544-0.","journal-title":"Oncogene"},{"issue":"4","key":"459_CR18","doi-asserted-by":"publisher","first-page":"110732","DOI":"10.1016\/j.celrep.2022.110732","volume":"39","author":"X Wang","year":"2022","unstructured":"Wang X, Qi Y, Wang Z, Wang L, Song A, Tao B, et al. RPAP2 regulates a transcription initiation checkpoint by inhibiting assembly of pre-initiation complex. Cell Rep. 2022;39(4):110732. https:\/\/doi.org\/10.1016\/j.celrep.2022.110732.","journal-title":"Cell Rep"},{"issue":"3","key":"459_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/carcin\/bgv005","volume":"36","author":"EH Nam","year":"2015","unstructured":"Nam EH, Lee Y, Moon B, Lee JW, Kim S. Twist1 and AP-1 cooperatively upregulate integrin \u03b15 expression to induce invasion and the epithelial-mesenchymal transition. Carcinogenesis. 2015;36(3):327\u201337. https:\/\/doi.org\/10.1093\/carcin\/bgv005.","journal-title":"Carcinogenesis"},{"issue":"2","key":"459_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3892\/mmr.2015.4649","volume":"13","author":"Y Song","year":"2016","unstructured":"Song Y, Qin X, Wang H, Miao R, Zhang Y, Miao C, et al. Effects of integrin \u03b15\u03b21 on the proliferation and migration of human aortic vascular smooth muscle cells. Mol Med Rep. 2016;13(2):1147\u201355. https:\/\/doi.org\/10.3892\/mmr.2015.4649.","journal-title":"Mol Med Rep"},{"issue":"20","key":"459_CR21","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W, Shen X, Su Y, Li J, et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 2022;82(20):3845\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4140.","journal-title":"Cancer Res"},{"issue":"7869","key":"459_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730\u20134. https:\/\/doi.org\/10.1038\/s41586-021-03741-7.","journal-title":"Nature"},{"issue":"6","key":"459_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/0008-5472.CAN-23-1916","volume":"84","author":"X Zhang","year":"2024","unstructured":"Zhang X, Su T, Wu Y, Cai Y, Wang L, Liang C, et al. N6-Methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression. Cancer Res. 2024;84(6):827\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1916.","journal-title":"Cancer Res"},{"issue":"8","key":"459_CR24","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.7150\/ijbs.93375","volume":"20","author":"S Yan","year":"2024","unstructured":"Yan S, Chen L, Zhuang H, Yang H, Yang Y, Zhang N, et al. HDAC inhibition sensitize hepatocellular carcinoma to lenvatinib via suppressing AKT activation. Int J Biol Sci. 2024;20(8):3046\u201360. https:\/\/doi.org\/10.7150\/ijbs.93375.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"459_CR25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","volume":"164","author":"J Wang","year":"2023","unstructured":"Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, et al. N6-Methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-Catenin and Hippo signaling pathways. Gastroenterology. 2023;164(6):990\u20131005. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.041.","journal-title":"Gastroenterology"},{"issue":"4","key":"459_CR26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","volume":"19","author":"J Pan","year":"2023","unstructured":"Pan J, Zhang M, Dong L, Ji S, Zhang J, Zhang S, et al. Genome-scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy. 2023;19(4):1184\u201398. https:\/\/doi.org\/10.1080\/15548627.2022.2117893.","journal-title":"Autophagy"},{"issue":"1","key":"459_CR27","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","volume":"14","author":"CON Leung","year":"2023","unstructured":"Leung CON, Yang Y, Leung RWH, So KKH, Guo HJ, Lei MML, et al. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat Commun. 2023;14(1):6699. https:\/\/doi.org\/10.1038\/s41467-023-42360-w.","journal-title":"Nat Commun"},{"issue":"26","key":"459_CR28","doi-asserted-by":"publisher","first-page":"16899","DOI":"10.1073\/pnas.242603899","volume":"99","author":"RL Strausberg","year":"2002","unstructured":"Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. 2002;99(26):16899\u2013903. https:\/\/doi.org\/10.1073\/pnas.242603899.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"459_CR29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nsmb.2853","volume":"21","author":"Z Ni","year":"2014","unstructured":"Ni Z, Xu C, Guo X, Hunter GO, Kuznetsova OV, Tempel W, et al. RPRD1A and RPRD1B are human RNA polymerase II C-terminal domain scaffolds for Ser5 dephosphorylation. Nat Struct Mol Biol. 2014;21(8):686\u201395. https:\/\/doi.org\/10.1038\/nsmb.2853.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"459_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7150\/thno.29055","volume":"9","author":"L Ren","year":"2019","unstructured":"Ren L, Chen H, Song J, Chen X, Lin C, Zhang X, et al. MiR-454-3p-mediated Wnt\/\u03b2-catenin signaling antagonists suppression promotes breast cancer metastasis. Theranostics. 2019;9(2):449\u201365. https:\/\/doi.org\/10.7150\/thno.29055.","journal-title":"Theranostics"},{"issue":"45","key":"459_CR31","doi-asserted-by":"publisher","first-page":"34621","DOI":"10.1074\/jbc.M110.148791","volume":"285","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhang Y, Zhang H, Yang X, Wang Y, Ren F, et al. p15RS attenuates Wnt\/{beta}-catenin signaling by disrupting {beta}-catenin\u00b7TCF4 Interaction. J Biol Chem. 2010;285(45):34621\u201331. https:\/\/doi.org\/10.1074\/jbc.M110.148791.","journal-title":"J Biol Chem"},{"issue":"10","key":"459_CR32","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.4161\/cc.20400","volume":"11","author":"X Zhang","year":"2012","unstructured":"Zhang X, Cao Q, Liu X, Liu S, Wang J, Sun S, et al. Cellular and molecular evidence for malignancy-inhibitory functions of p15RS. Cell Cycle. 2012;11(10):1988\u201398. https:\/\/doi.org\/10.4161\/cc.20400.","journal-title":"Cell Cycle"},{"issue":"1","key":"459_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41419-021-04447-4","volume":"13","author":"X Feng","year":"2021","unstructured":"Feng X, Jiang T, Yang C, Pang S, Ding Z, Hu H, et al. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death Dis. 2021;13(1):6. https:\/\/doi.org\/10.1038\/s41419-021-04447-4.","journal-title":"Cell Death Dis"},{"issue":"6","key":"459_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673\u201387. https:\/\/doi.org\/10.1016\/s0092-8674(02)00971-6.","journal-title":"Cell"},{"issue":"1","key":"459_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-018-0763-x","volume":"37","author":"R Huang","year":"2018","unstructured":"Huang R, Rofstad EK. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res. 2018;37(1):92. https:\/\/doi.org\/10.1186\/s13046-018-0763-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"459_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1083\/jcb.201502040","volume":"210","author":"NR Paul","year":"2015","unstructured":"Paul NR, Allen JL, Chapman A, Morlan-Mairal M, Zindy E, Jacquemet G, et al. \u03b15\u03b21 integrin recycling promotes Arp2\/3-independent cancer cell invasion via the formin FHOD3. J Cell Biol. 2015;210(6):1013\u201331. https:\/\/doi.org\/10.1083\/jcb.201502040.","journal-title":"J Cell Biol"},{"issue":"1","key":"459_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1083\/jcb.201111077","volume":"197","author":"M Nagae","year":"2012","unstructured":"Nagae M, Re S, Mihara E, Nogi T, Sugita Y, Takagi J. Crystal structure of \u03b15\u03b21 integrin ectodomain: atomic details of the fibronectin receptor. J Cell Biol. 2012;197(1):131\u201340. https:\/\/doi.org\/10.1083\/jcb.201111077.","journal-title":"J Cell Biol"},{"key":"459_CR38","doi-asserted-by":"publisher","unstructured":"Lv X, Li Z, Guan J, Hu S, Zhang J, Lan Y, et al. Porcine hemagglutinating encephalomyelitis virus activation of the integrin \u03b15\u03b21-FAK-Cofilin pathway causes cytoskeletal rearrangement to promote its invasion of N2a cells. J Virol. 2019;93(5). https:\/\/doi.org\/10.1128\/JVI.01736-18.","DOI":"10.1128\/JVI.01736-18"},{"issue":"7","key":"459_CR39","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","volume":"40","author":"F Pantano","year":"2021","unstructured":"Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, et al. Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene. 2021;40(7):1284\u201399. https:\/\/doi.org\/10.1038\/s41388-020-01603-6.","journal-title":"Oncogene"},{"issue":"10","key":"459_CR40","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/jcb.25189","volume":"116","author":"C Pelillo","year":"2015","unstructured":"Pelillo C, Bergamo A, Mollica H, Bestagno M, Sava G. Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through \u03b15\u03b21 Integrin. J Cell Biochem. 2015;116(10):2385\u201396. https:\/\/doi.org\/10.1002\/jcb.25189.","journal-title":"J Cell Biochem"},{"issue":"6","key":"459_CR41","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1002\/jcb.26651","volume":"119","author":"X Cai","year":"2018","unstructured":"Cai X, Liu C, Zhang TN, Zhu YW, Dong X, Xue P. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 2018;119(6):4717\u201328. https:\/\/doi.org\/10.1002\/jcb.26651.","journal-title":"J Cell Biochem"},{"issue":"4","key":"459_CR42","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3892\/or.2016.4985","volume":"36","author":"C Gong","year":"2016","unstructured":"Gong C, Yang Z, Wu F, Han L, Liu Y, Gong W. miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1. Oncol Rep. 2016;36(4):2177\u201383. https:\/\/doi.org\/10.3892\/or.2016.4985.","journal-title":"Oncol Rep"},{"issue":"6","key":"459_CR43","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s10528-021-10069-4","volume":"59","author":"S Cui","year":"2021","unstructured":"Cui S, Yang CL, Chen DY. LncRNA EWSAT1 regulates the tumorigenesis of NSCLC as a ceRNA by modulating miR-330-5p\/ITGA5 axis. Biochem Genet. 2021;59(6):1441\u201356. https:\/\/doi.org\/10.1007\/s10528-021-10069-4.","journal-title":"Biochem Genet"},{"key":"459_CR44","doi-asserted-by":"publisher","first-page":"e5180","DOI":"10.7717\/peerj.5180","volume":"6","author":"L Cao","year":"2018","unstructured":"Cao L, Chen Y, Zhang M, Xu DQ, Liu Y, Liu T, et al. Identification of hub genes and potential molecular mechanisms in gastric cancer by integrated bioinformatics analysis. PeerJ. 2018;6:e5180. https:\/\/doi.org\/10.7717\/peerj.5180.","journal-title":"PeerJ"},{"issue":"3","key":"459_CR45","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1002\/cam4.5110","volume":"12","author":"Y Shi","year":"2023","unstructured":"Shi Y, Shang J, Li Y, Zhong D, Zhang Z, Yang Q, et al. ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma. Cancer Med. 2023;12(3):3786\u201396. https:\/\/doi.org\/10.1002\/cam4.5110.","journal-title":"Cancer Med"},{"key":"459_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132\u201349. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.001.","journal-title":"Pharmacol Ther"},{"issue":"19","key":"459_CR47","doi-asserted-by":"publisher","first-page":"e104743","DOI":"10.15252\/embj.2020104743","volume":"39","author":"I Acebr\u00f3n","year":"2020","unstructured":"Acebr\u00f3n I, Righetto RD, Schoenherr C, de Buhr S, Redondo P, Culley J, et al. Structural basis of Focal Adhesion Kinase activation on lipid membranes. EMBO J. 2020;39(19):e104743. https:\/\/doi.org\/10.15252\/embj.2020104743.","journal-title":"EMBO J"},{"issue":"4","key":"459_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1023\/a:1023725029589","volume":"22","author":"V Gabarra-Niecko","year":"2003","unstructured":"Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003;22(4):359\u201374. https:\/\/doi.org\/10.1023\/a:1023725029589.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"459_CR49","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","volume":"15","author":"F Haderk","year":"2024","unstructured":"Haderk F, Chou YT, Cech L, Fern\u00e1ndez-M\u00e9ndez C, Yu J, Olivas V, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024;15(1):3741. https:\/\/doi.org\/10.1038\/s41467-024-47423-0.","journal-title":"Nat Commun"},{"issue":"1","key":"459_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-023-00471-6","volume":"13","author":"M Qiao","year":"2024","unstructured":"Qiao M, Zhou F, Liu X, Jiang T, Wang H, Li X, et al. Targeting focal adhesion kinase boosts immune response in KRAS\/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):11. https:\/\/doi.org\/10.1186\/s40164-023-00471-6.","journal-title":"Exp Hematol Oncol"},{"key":"459_CR51","doi-asserted-by":"publisher","first-page":"102559","DOI":"10.1016\/j.nano.2022.102559","volume":"43","author":"J Choi","year":"2022","unstructured":"Choi J, Park S. A nanomechanical strategy involving focal adhesion kinase for overcoming drug resistance in breast cancer. Nanomedicine. 2022;43:102559. https:\/\/doi.org\/10.1016\/j.nano.2022.102559.","journal-title":"Nanomedicine"},{"key":"459_CR52","doi-asserted-by":"publisher","first-page":"117288","DOI":"10.1016\/j.ejmech.2025.117288","volume":"286","author":"Y Wei","year":"2025","unstructured":"Wei Y, He X, Long Z, Le Y, Liu L, Yan L. Discovery of noncovalent diaminopyrimidine-based inhibitors for glioblastoma via a dual FAK\/DNA targeting strategy. Eur J Med Chem. 2025;286:117288. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117288.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"459_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/1568009618666180706165222","volume":"19","author":"A Levy","year":"2019","unstructured":"Levy A, Alhazzani K, Dondapati P, Alaseem A, Cheema K, Thallapureddy K, et al. Focal adhesion kinase in ovarian cancer: a potential therapeutic target for platinum and taxane-resistant tumors. Curr Cancer Drug Targets. 2019;19(3):179\u201388. https:\/\/doi.org\/10.2174\/1568009618666180706165222.","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"459_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1124\/jpet.117.240507","volume":"363","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Guo X, Choksi R. Activation of focal adhesion kinase and Src mediates acquired sorafenib resistance in A549 human lung adenocarcinoma xenografts. J Pharmacol Exp Ther. 2017;363(3):428\u201343. https:\/\/doi.org\/10.1124\/jpet.117.240507.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"459_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/mc.23644","volume":"63","author":"W Hou","year":"2024","unstructured":"Hou W, Gad SA, Ding X, Dhanarajan A, Qiu W. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1. Mol Carcinog. 2024;63(1):173\u201389. https:\/\/doi.org\/10.1002\/mc.23644.","journal-title":"Mol Carcinog"},{"issue":"8","key":"459_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851\u201360. https:\/\/doi.org\/10.1038\/nm.4123.","journal-title":"Nat Med"},{"issue":"1","key":"459_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/jtim-2025-0051","volume":"14","author":"X Liu","year":"2026","unstructured":"Liu X, Wang F, Cui P, Zheng Z, Zhang N, Kong R. Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma. J Transl Int Med. 2026;14(1):64\u201378. https:\/\/doi.org\/10.1515\/jtim-2025-0051.","journal-title":"J Transl Int Med"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00459-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00459-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00459-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:12:32Z","timestamp":1779433952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00459-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00459-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice: The Animal Care and Use Committee of Shanghai Eastern Hepatobiliary Surgery Hospital has reviewed and approved the protocol for the use of animals in this study. No: EDWLL-029. Human specimens: Clinical specimens were approved by the Ethics Committee of Shanghai Eastern Hepatobiliary Surgery Hospital. Written informed consent was obtained from all participants. No: S2022007-CS001(III).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}